Blaukat A - Search Results

1

DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia.

Haines E, Nishida Y, Carr MI, Montoya RH, Ostermann LB, Zhang W, Zenke FT, Blaukat A, Andreeff M, Vassilev LT. Haines E, et al. Among authors: blaukat a. Sci Rep. 2021 Jun 9;11(1):12148. doi: 10.1038/s41598-021-90500-3. Sci Rep. 2021. PMID: 34108527 Free PMC article.

2

Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition-Associated Checkpoint Abrogation.

Mikami K, Medová M, Nisa L, Francica P, Glück AA, Tschan MP, Blaukat A, Bladt F, Aebersold DM, Zimmer Y. Mikami K, et al. Among authors: blaukat a. Mol Cancer Res. 2015 Dec;13(12):1544-53. doi: 10.1158/1541-7786.MCR-15-0022. Epub 2015 Sep 10. Mol Cancer Res. 2015. PMID: 26358474 Free article.

3

Overcoming hypoxia-induced tumor radioresistance in non-small cell lung cancer by targeting DNA-dependent protein kinase in combination with carbon ion irradiation.

Klein C, Dokic I, Mairani A, Mein S, Brons S, Häring P, Haberer T, Jäkel O, Zimmermann A, Zenke F, Blaukat A, Debus J, Abdollahi A. Klein C, et al. Among authors: blaukat a. Radiat Oncol. 2017 Dec 29;12(1):208. doi: 10.1186/s13014-017-0939-0. Radiat Oncol. 2017. PMID: 29287602 Free PMC article.

4

Therapeutic Implications of p53 Status on Cancer Cell Fate Following Exposure to Ionizing Radiation and the DNA-PK Inhibitor M3814.

Sun Q, Guo Y, Liu X, Czauderna F, Carr MI, Zenke FT, Blaukat A, Vassilev LT. Sun Q, et al. Among authors: blaukat a. Mol Cancer Res. 2019 Dec;17(12):2457-2468. doi: 10.1158/1541-7786.MCR-19-0362. Epub 2019 Sep 24. Mol Cancer Res. 2019. PMID: 31551253 Free article.

5

DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia.

Carr MI, Zimmermann A, Chiu LY, Zenke FT, Blaukat A, Vassilev LT. Carr MI, et al. Among authors: blaukat a. Front Oncol. 2020 Feb 13;10:127. doi: 10.3389/fonc.2020.00127. eCollection 2020. Front Oncol. 2020. PMID: 32117773 Free PMC article.

6

Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.

Zenke FT, Zimmermann A, Sirrenberg C, Dahmen H, Kirkin V, Pehl U, Grombacher T, Wilm C, Fuchss T, Amendt C, Vassilev LT, Blaukat A. Zenke FT, et al. Among authors: blaukat a. Mol Cancer Ther. 2020 May;19(5):1091-1101. doi: 10.1158/1535-7163.MCT-19-0734. Epub 2020 Mar 27. Mol Cancer Ther. 2020. PMID: 32220971

7

DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGFβ/PD-L1 Targeted Cancer Immunotherapy.

Carr MI, Chiu LY, Guo Y, Xu C, Lazorchak AS, Yu H, Qin G, Qi J, Marelli B, Lan Y, Sun Q, Czauderna F, Zenke FT, Blaukat A, Vassilev LT. Carr MI, et al. Among authors: blaukat a. Mol Cancer Res. 2022 Apr 1;20(4):568-582. doi: 10.1158/1541-7786.MCR-21-0612. Mol Cancer Res. 2022. PMID: 34980594 Free PMC article.

8

A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies.

Zimmermann A, Zenke FT, Chiu LY, Dahmen H, Pehl U, Fuchss T, Grombacher T, Blume B, Vassilev LT, Blaukat A. Zimmermann A, et al. Among authors: blaukat a. Mol Cancer Ther. 2022 Jun 1;21(6):859-870. doi: 10.1158/1535-7163.MCT-21-0934. Mol Cancer Ther. 2022. PMID: 35405736 Free PMC article.

9

Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors.

Turchick A, Zimmermann A, Chiu LY, Dahmen H, Elenbaas B, Zenke FT, Blaukat A, Vassilev LT. Turchick A, et al. Among authors: blaukat a. Mol Cancer Ther. 2023 Jul 5;22(7):859-872. doi: 10.1158/1535-7163.MCT-22-0685. Mol Cancer Ther. 2023. PMID: 37079339 Free PMC article.

10

Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models.

Friese-Hamim M, Ortiz Ruiz MJ, Bogatyrova O, Keil M, Rohdich F, Blume B, Leuthner B, Czauderna F, Hahn D, Jabs J, Jaehrling F, Heinrich T, Kellner R, Chan K, Tong AHY, Wienke D, Moffat J, Blaukat A, Zenke FT. Friese-Hamim M, et al. Among authors: blaukat a. Mol Cancer Ther. 2024 Feb 1;23(2):159-173. doi: 10.1158/1535-7163.MCT-23-0102. Mol Cancer Ther. 2024. PMID: 37940144 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

63 results

Search Page

Filters